Zimmer Biomet Holdings Inc (ZBH) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Zimmer Biomet Holdings Inc stock $81.34, price $110, that is 26.2% below the price, quality 65 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $79.16 – $141.22 · fair‑value band $52.85 – $101.67 · the $110.15 price screens above the $81.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Zimmer Biomet Holdings in your weekly email
Every Wednesday you see whether Zimmer Biomet Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Show moreShow less
The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest.
It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups.
It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care.
The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Stock analysis
Zimmer Biomet Holdings Inc (ZBH) currently trades at $110.15, while our model-based Fair Value estimate is $81.34, 26% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $90.74 per share, and 6 of the 24 models we run sit above the $110.15 price.
Bear case: the Dividend Discount group reads lowest at $16.31, and 18 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $52.85 (bear) to $101.67 (bull), the price of $110.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Zimmer Biomet Holdings Inc reported revenue of $8.2B in FY2025 versus $6.8B in FY2021, a compound +4.8%/yr. Reported net income was $705M in FY2025, compounding +15.1%/yr from FY2021.
Key figures
Market cap $21.2B Large · P/E ratio 26.7 · P/S ratio 2.50 · EPS (TTM) $4.12 · Dividend yield 0.9% · Net margin 9.5% · Return on equity 6.4% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −26%, ZBH screens richer than that median.
Fair Value models
Bear$52.85Fair Value $81.34Bull$101.67
Price $110.15 · Downside -26.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.68 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors sold shares worth $1.2M and none bought.
SaleKevin R ThornalGrp Pres-Global Business5,691 shares at $92.95$528,978Sep 11, 2026
SaleChad F PhippsOfficer3,000 shares at $98.35$295,050Sep 4, 2026
SaleSang YiGroup President, Asia Pacific2× since Feb 12, 2026: 6,000 shares, avg. $84.95$509,706May 29, 2026
SaleLori WinklerSVP and CHRO2,650 shares at $94.66$250,849Mar 12, 2026
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.2%
Dividend (yield on the price)0.9%
Per share before 2022divided by the spin-off factor 1.03
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: −0.2% / 9.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +1.9% a year for the price and +1.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Accelerating shift to dedicated U.S. sales specialists supports commercial execution in orthopedics, yet elevated leverage and ongoing restructuring continue to limit returns.
Main risk: The substantial long-term debt from the 2015 merger could constrain Zimmer Biomet's ability to pursue acquisitions or refinance maturing obligations on favorable terms amid ongoing robotics investments by peers.
Bull case: Zimmer Biomet could strengthen its position by expanding its ROSA and acquired autonomous robotics portfolio with AI enhancements to capture more procedures and offset competitive pressures while generating recurring data revenue.
Bear case: Persistent share losses to Stryker's robotics combined with debt constraints and EU MDR compliance hurdles could limit innovation spending and erode margins or European revenues over several years.
Zimmer Biomet is moving its U.S. sales force to dedicated specialists faster than planned, with the CEO reporting less customer disruption and turnover than expected in the early phases. The company raised its 2026 revenue and earnings outlook on the back of this progress while still facing the second half of the multi-year restructuring. Will the full shift strengthen commercial execution in orthopedics enough to offset any lingering integration challenges?
Compare Zimmer Biomet Holdings Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Above median
Fair Value upside−26.2% · Below median
Profitability
Return on equity (12 months)6.4% · Above median
Return on assets3.1% · Above median
Net margin (12 months)9.5% · Above median
Operating margin (12 months)18.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.8% · Below median
Dividend yield (12 months)0.9% · Bottom 25%
Balance sheet
Debt / equity0.55× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)26.7× · Pricier than median
P/B1.67× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.50× · Cheaper than median
Price / free cash flow14.4× · Cheapest 25%
EV/EBITDA10.9× · Cheaper than median
PEG0.57× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)24· sector 36
PAST (return on equity)26· sector 16
HEALTH (low debt)73· sector 98
DIVIDEND (yield)17· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Zimmer Biomet Holdings Inc (ZBH) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $81.34 versus a price of $110.15, about 26% lower (overvalued).
What is the fair value of ZBH?
Our model-based fair value for Zimmer Biomet Holdings Inc is $81.34 (as of Nov 5, 2026), built from audited fundamentals. The current price: $110.15.
What is the quality score of ZBH?
Zimmer Biomet Holdings Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zimmer Biomet Holdings Inc (ZBH)?
Our model-based price target is the fair value of $81.34 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $52.85, optimistic scenario $101.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Zimmer Biomet Holdings Inc stock forecast for 2026?
Our models put fair value at $81.34, about 26% lower versus a price of $110.15 (overvalued). Cautious scenario $52.85, optimistic scenario $101.67. The calculation is refreshed regularly with new filings.
What is the revenue of Zimmer Biomet Holdings Inc (ZBH)?
Zimmer Biomet Holdings Inc reported trailing-twelve-month revenue of about $8.5B (latest available figure, as of Nov 5, 2026).
Does Zimmer Biomet Holdings Inc pay a dividend?
Zimmer Biomet Holdings Inc currently shows a dividend yield of 0.87% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Zimmer Biomet Holdings Inc (ZBH)?
For today's price to be fair in a discounted-cash-flow model, Zimmer Biomet Holdings Inc would have to grow free cash flow by +4.3 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of ZBH use?
Our models discount Zimmer Biomet Holdings Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.49, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zimmer Biomet Holdings Inc that is +4.3 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Zimmer Biomet Holdings Inc (ZBH) delivered so far?
Over the past 5 years revenue at Zimmer Biomet Holdings Inc grew +6.1 % a year. The price currently implies +4.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zimmer Biomet Holdings Inc (ZBH) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Zimmer Biomet Holdings Inc (+4.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zimmer Biomet Holdings Inc (ZBH)?
The free-cash-flow yield on the price is 6.93 %: that much free cash flow Zimmer Biomet Holdings Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zimmer Biomet Holdings Inc (ZBH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zimmer Biomet Holdings Inc it is $81.34 per share (as of Nov 5, 2026), against a price of $110.15. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Zimmer Biomet Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, ZBH trades above its calculated fair value: price $110.15, fair value $81.34, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZBH?
No. The price is what the market pays today ($110.15); the fair value is what the company's own numbers justify ($81.34). For Zimmer Biomet Holdings Inc the two are $28.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zimmer Biomet Holdings Inc worth?
The market values Zimmer Biomet Holdings Inc at about $21.2B (market capitalisation, as of Nov 5, 2026). Per share that is $110.15; our models calculate a fair value of $81.34 per share.
What do the bullish and bearish scenarios say about ZBH?
Our models span a range for Zimmer Biomet Holdings Inc: cautious scenario $52.85, base $81.34, optimistic $101.67 per share (as of Nov 5, 2026, price $110.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZBH?
Zimmer Biomet Holdings Inc trades at a price-to-earnings ratio of 26.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $81.34 is built from several models across several years. Other multiples: PEG 0.6, P/B 1.7, P/S 2.5, EV/EBITDA 10.9.
What is the PEG ratio of ZBH?
The PEG ratio of Zimmer Biomet Holdings Inc is 0.57 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Zimmer Biomet Holdings Inc (ZBH)?
Balance-sheet figures for Zimmer Biomet Holdings Inc (as of Nov 5, 2026): return on equity 6.4%, debt of 0.55 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is ZBH from its 52-week high?
Zimmer Biomet Holdings Inc trades at $110.15, at its 52-week high of $110.15 and 39% above the low of $79.16 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $81.34 is for.
Which stocks are comparable to Zimmer Biomet Holdings Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zimmer Biomet Holdings Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $110.15, calculated fair value $81.34 (−26%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZBH calculated?
We run Zimmer Biomet Holdings Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $81.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Zimmer Biomet Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zimmer Biomet Holdings Inc (ZBH)?
The closing price on Nov 4, 2026 was $110.15. Our model-based fair value is $81.34, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zimmer Biomet Holdings Inc right now?
The price sits above even our optimistic bull case ($101.67). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($52.85 to $101.67) leaves room in how you read the outcome.
Where does the earnings growth of Zimmer Biomet Holdings Inc (ZBH) come from?
Earnings per share at Zimmer Biomet Holdings Inc grew +8.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.8 %, EBIT margin +3.2 %, tax rate +1.5 %, residual (interest, one-offs) +1.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zimmer Biomet Holdings Inc
How large is the market capitalisation of Zimmer Biomet Holdings Inc (ZBH)?
The market capitalisation of Zimmer Biomet Holdings Inc is $21.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zimmer Biomet Holdings Inc (ZBH)?
The price-to-sales ratio of Zimmer Biomet Holdings Inc is 2.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zimmer Biomet Holdings Inc (ZBH)?
Earnings per share at Zimmer Biomet Holdings Inc are $4.12 (price ÷ EPS = P/E 26.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zimmer Biomet Holdings Inc (ZBH)?
The dividend yield of Zimmer Biomet Holdings Inc is 0.9% (payout 23.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zimmer Biomet Holdings Inc (ZBH)?
The net margin of Zimmer Biomet Holdings Inc is 9.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zimmer Biomet Holdings Inc (ZBH)?
The return on equity (ROE) of Zimmer Biomet Holdings Inc is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zimmer Biomet Holdings Inc (ZBH)?
On an EBIT basis the return on assets of Zimmer Biomet Holdings Inc is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zimmer Biomet Holdings Inc (ZBH)?
The operating margin of Zimmer Biomet Holdings Inc is 18.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zimmer Biomet Holdings Inc (ZBH)?
Revenue at Zimmer Biomet Holdings Inc is growing +4.8% versus a year earlier (3y avg +5.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zimmer Biomet Holdings Inc (ZBH)?
Earnings per share at Zimmer Biomet Holdings Inc are growing +33.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Zimmer Biomet Holdings Inc (ZBH) carry?
The net debt of Zimmer Biomet Holdings Inc is $6.9B (fiscal year 2025, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zimmer Biomet Holdings Inc in the live analysis
One click puts Zimmer Biomet Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026